A Dutch neuromodulation developer has raised $60 million to complete the development of its minimally invasive implant for ...

The company’s MySalvia system uses neuromodulation to alleviate the frequency and intensity of chronic migraines.

Shares of NeuroPace (NASDAQ:NPCE) shed ~24% in the premarket on Tuesday after the MedTech said that its NAUTILUS study ...

NeuroPace announced preliminary one-year results from its clinical study evaluating neuromodulation therapy for generalized ...

Up to 40% of all epilepsy diagnoses in the United States are of the drug-resistant variety, affecting 1.2 million people ...

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical ...

Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which treats chronic migraine. The funds will ...

Salvia BioElectronics announced today that it completed a $60 million Series B financing round to support its migraine ...

Urinary and bowel disorders, manifesting as symptoms like frequent urination or difficulty in bowel movements, can greatly ...

Waataja. “Our Diabetes Neuromodulation technology utilizes Hypoglycemia Vagus Nerve Stimulation (HVNS), targeting stimulation of the sub-diaphragmatic posterior vagus nerve (PVN) to rapidly ...